M&A Deal Summary

Pfizer Acquires Therachon AG

On May 8, 2019, Pfizer acquired life science company Therachon AG for 810M USD

Acquisition Highlights
  • This is Pfizer’s 29th transaction in the Life Science sector.
  • This is Pfizer’s 13th largest (disclosed) transaction.
  • This is Pfizer’s 2nd transaction in Switzerland.

M&A Deal Summary
Date 2019-05-08
Target Therachon AG
Sector Life Science
Buyer(s) Pfizer
Deal Type Add-on Acquisition
Deal Value 810M USD
Advisor(s) Goldman Sachs (Financial)
Cooley
Homburger (Legal)

Target

Therachon AG

Basel, Switzerland
Therachon AG is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with significant unmet need. Therachon AG was founded in 2014 and is based in Basel, Switzerland.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States
Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.

DEAL STATS #
Overall 33 of 44
Sector (Life Science) 29 of 39
Type (Add-on Acquisition) 23 of 31
Country (Switzerland) 2 of 3
Year (2019) 2 of 3
Size (of disclosed) 13 of 22
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-03-20 Vivet Therapeutics SAS

Paris, United States

Vivet Therapeutics is an emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases. Vivet is building a diversified gene therapy pipeline based on novel adeno-associated virus (AAV) technologies developed through its partnerships with, and exclusive licenses from, the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigación Medica Aplicada (CIMA), University of Navarra based in Pamplona, Spain.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-06-17 Array BioPharma

Boulder, Colorado, United States

Array BioPharma, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Six Phase 3 studies on Array invented drugs, binimetinib (partnered with Novartis) and selumetinib (partnered with AstraZeneca), are currently enrolling patients with cancer. Array BioPharma, Inc. was formed in 1998 and is headquartered in Boulder, Colorado.

Buy $11.4B
Mergr

Product

Company

Legal